Advertisement

Topics

PubMed Journals Articles About "NSAV Announces Launch Medical Cannabis Technology Business" RSS

20:53 EST 15th January 2019 | BioPortfolio

NSAV Announces Launch Medical Cannabis Technology Business PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest NSAV Announces Launch Medical Cannabis Technology Business articles that have been published worldwide.

More Information about "NSAV Announces Launch Medical Cannabis Technology Business" on BioPortfolio

We have published hundreds of NSAV Announces Launch Medical Cannabis Technology Business news stories on BioPortfolio along with dozens of NSAV Announces Launch Medical Cannabis Technology Business Clinical Trials and PubMed Articles about NSAV Announces Launch Medical Cannabis Technology Business for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NSAV Announces Launch Medical Cannabis Technology Business Companies in our database. You can also find out about relevant NSAV Announces Launch Medical Cannabis Technology Business Drugs and Medications on this site too.

Showing "NSAV Announces Launch Medical Cannabis Technology Business" PubMed Articles 1–25 of 14,000+

Prevalence and correlates of non-medical only compared to self-defined medical and non-medical cannabis use, Canada, 2015.

The Canadian federal government has committed to legalizing non-medical cannabis use by adults in 2018. Medical use was legalized in 2001; however, not all people reporting medical use have medical authorization. To prepare for monitoring the effects of the policy change, a greater understanding of the prevalence of cannabis use and the characteristics of all cannabis users is needed.


International differences in patterns of cannabis use among youth: Prevalence, perceptions of harm, and driving under the influence in Canada, England & United States.

Cannabis is the most widely used illicit substance in the world. An increasing number of jurisdictions have legalized medical and non-medical cannabis; comparisons across jurisdictions can help evaluate the impact of these policy innovations. The current study examined patterns of cannabis use among youth in Canada (CA), England (EN) and the United States (US). At the time of study, non-medical cannabis use was prohibited federally in all three countries; however, medical cannabis was accessible with varyin...

Diabetes mellitus caused by cannabis oil.

The effects and side effects of medical cannabis are not well-established. In 2018, cannabis was approved as a medical drug in Denmark - giving all doctors the opportunity to subscribe medical cannabis to their patients. In this case report a 64-year-old kidney-transplanted woman started cannabis droplets due to chronic back pain, which resulted in increased appetite, weight gain and development of diabetes mellitus. Patients with an increased risk of developing diabetes may be more prone to this under the ...


Correct knowledge of medical cannabis legal status in one's own state: Differences between adolescents and adults in the United States, 2004-2013.

Studies have found age-specific effects of medical cannabis laws (MCLs), particularly affecting adult cannabis use but not adolescent use. We examined whether age differences in MCL knowledge are in accordance with age differences in MCL effects on cannabis use.

A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age.

There is a rapidly evolving legal and medical culture around cannabis, with corresponding changes in the demographics of users. For instance, the percentage of the aging population accessing cannabis is growing substantially, outpacing other age groups. The goals of this study were to describe the acute effects of cannabis, subjective experiences of withdrawal, and beliefs around the addictiveness of cannabis, as well as to determine whether these effects differ as a function of age or reason for use (medic...

Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.

The recent release of a medical cannabis strain has given a new impulse for the study of cannabis in Italy. The National Health Service advises to consume medical cannabis by vaporizing, in decoction or oil form. This is the first study that explores the pharmacokinetics and tolerability of a single oral dose of cannabis as decoction (200 ml) or in olive oil (1 ml), as a first step to improve the prescriptive recommendations.

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed question...

Trends in Publications on Medical Cannabis from the Year 2000.

Widespread use of cannabis as a drug and passage of legislation on its use should lead to an increase in the number of scientific publications on cannabis. The aim of this study was to compare trends in scientific publication for papers on medical cannabis, papers on cannabis in general, and all papers between the years 2000 and 2017. A search of PubMed and Web of Science was conducted. The overall number of scientific publications in PubMed increased 2.5-fold. In contrast, the number of publications on can...

Medical cannabis legalization and state-level prevalence of serious mental illness in the National Survey on Drug Use and Health (NSDUH) 2008-2015.

Although research has established a link between cannabis legalization and use, and cannabis use and mental health, the relationship between medical cannabis legalization and mental health remains uncharacterized. This analysis investigated the relationship between state medical cannabis laws (restrictive, i.e. covering a narrow set of medical conditions; or liberal, i.e. covering a broad range of medical conditions), whether the law permits patients to petition their physician to approve medical cannabis u...

Accumulation of bioactive metabolites in cultivated medical Cannabis.

There has been an increased use of medical Cannabis in the United States of America as more states legalize its use. Complete chemical analyses of this material can vary considerably between producers and is often not fully provided to consumers. As phytochemists in a state with legal medical Cannabis we sought to characterize the accumulation of phytochemicals in material grown by licensed commercial producers. We report the development of a simple extraction and analysis method, amenable to use by commerc...

Understanding emerging forms of cannabis use through an online cannabis community: An analysis of relative post volume and subjective highness ratings.

Legalization of medical and recreational cannabis has coincided with an increase in novel forms of cannabis use and a burgeoning cannabis product industry. This research seeks to understand the occurrence of discussions about these emerging and traditional forms of use in an online social media discussion forum.

Comparing medical and recreational cannabis use among employees: associations with health and work-related outcomes.

Nearly one in five US employees reports having used cannabis in the past year. As policies and laws regarding cannabis use rapidly change, concerns have arisen over employees' use of cannabis, for both medical and recreational purposes. While extant workplace research has not distinguished between types of cannabis users, other studies have found that medical users are clinically and socio-demographically different from non-medical users. This study utilized a sample of employed National Survey on Drug Use ...

The effects of medical marijuana laws on cannabis-involved driving.

This study uses data from the Fatality Analysis Reporting System and a differences-in-differences model to examine the effect of state medical marijuana laws (MMLs) on cannabis-involved driving among U.S. drivers involved in a fatal crash between 1993-2014. Findings indicate that MMLs in general have a null effect on cannabis-positive driving, as do state laws with specific supply provisions including home cultivation and unlicensed or quasi-legal dispensaries. Only in jurisdictions with state-licensed medi...

Patients' and clinicians' perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care.

The prevalence of opioid-associated morbidity and mortality underscores the need for research on non-opioid treatments for chronic non-cancer pain (CNCP). Pain is the most common medical condition for which patients request medical cannabis. Limited research indicates that patients are interested in cannabis as a potential addition to or replacement for opioid medication. This analysis reports on CNCP patient and clinician perceptions about the co-use of cannabis and opioids for CNCP management.

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain.

The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including...

Short-term and long-term effects of cannabis use.

Cannabis is used worldwide. So, it is necessary to stay especially concerned by the medical and social consequences of its use. For a long time, it was seen as a " soft drug ", in reference to the apparent low medical risk related to its use. However, the psycho-social consequences of cannabis use albeit of major importance are commonly neglected. Furthermore, danger for the health does exist, both from psychiatry and somatic medicine points of view. The danger is growing especially due to the apparition on...

Attentional bias to cannabis cues in cannabis users but not cocaine users.

Attentional bias to drug cues has been associated with the problematic use of drugs, including cannabis. The cognitive mechanisms underlying this bias are not fully understood. The purpose of this study was to determine whether cannabis-cue attentional bias is associated with disruptions in attentional processing. To this end, a novel cannabis-cue visual probe task that incorporated eye tracking technology and attention-based metrics derived from signal detection theory was administered to seventeen individ...

Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol.

Research typically characterizes cannabis use by self-report of cannabis intake frequency. In an effort to better understand relationships between measures of cannabis use, we evaluated if Δ-9-tetrahydrocannabinol (THC) and metabolite concentrations (biometrics) were associated with a calibrated timeline followback (TLFB) assessment of cannabis use.

Cannabis Use and Bleomycin: An Overview and Case Study of Pulmonary Toxicity.

Legalization efforts in many states have heightened awareness of the medicinal uses of cannabis, and oncology nurses are more frequently caring for patients who have used or are using cannabis. Significant epidemiologic data on the prevalence of cannabis use in patients with cancer are not yet available, and not much is known about the effects of cannabis on cancer treatment.

Price Elasticity of Illegal vs Legal Cannabis: A Behavioral Economic Substitutability Analysis.

The evolving legal status of cannabis worldwide necessitates evidence-based regulatory policies to minimize risks associated with cannabis misuse. A prominent concern is the impact legalization may have on the illegal cannabis market, including whether illegal cannabis will serve as a substitute for legal cannabis. Empirical data on this issue are virtually nonexistent. This study used behavioral economcis to investigate substitutability of legal and illegal cannabis in legalized catchment areas in the U.S.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

This study was aimed at investigating the availability and prescription of different medicinal variants of cannabis and their status in European countries.

Community variation in adolescent cannabis use in Australia and the Netherlands.

While controversial, cannabis use is common, and often begins in adolescence. In Australia and the Netherlands, cannabis use is understood and legislated within a harm-minimisation framework. In Australia it is illegal to purchase or consume cannabis. Cannabis use in the Netherlands is illegal, except in licensed coffee shops where the sale and consumption of small amounts (5 g) are permitted.

Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study.

In patients with cancer, the use of medical cannabis has increased significantly during the recent years. There is evidence that cannabis consumption may affect cognitive performance; however, this potential effect has not been investigated prospectively in patients with cancer to date. We aimed to evaluate the effect of cannabis consumption on cognitive abilities as well as on symptom relief in patients with cancer during chemotherapy treatment.

Typology of cannabis use among adults: A latent class approach to risk and protective factors.

Cannabis is among the most widely used substances worldwide. The United States has seen an increase in the number of adult daily cannabis users and in the number of adults diagnosed with cannabis use disorder. However, little work has examined patterns of use or unique subgroups of adult cannabis users, which may be useful in developing targeted treatment interventions for problematic cannabis users. Therefore, the current study used latent profile analysis to identify whether cannabis users can be categori...

Beyond deficit and harm reduction: Incorporating the spectrum of wellness as an interpretive framework for cannabis consumption.

The cannabis academic literature is informed by dominant deficit, public health and harm reduction frameworks. However, a large majority of cannabis consumption appears to place outside the scope of these models that prioritise the identification and limitation of negative impacts. As such there are apparent analytical blind spots pertaining to: non-problematic use of cannabis (as defined by Global Commission on Drug Policy); the intersection of medical and recreational intents of use; and pleasure. This pa...


Advertisement
Quick Search
Advertisement
Advertisement